Begin main content

CADTH pan-Canadian Oncology Drug Review

The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.

The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.

Drug Review Updates

Crizotinib (Xalkori) for ROS1-Positive Non-Small Cell Lung Cancer
(Final Recommendation Issued as of May 23, 2019)

Palbociclib (Ibrance) for Advanced or Metastatic Breast Cancer
(Notification to Implement Issued as of May 21, 2019)

Dabrafenib & Trametinib (Tafinlar & Mekinist) in combo for Melanoma Adjuvant Therapy
(Notification to Implement Issued as of May 21, 2019)

Durvalumab (Imfinzi) for Non-Small Cell Lung Cancer
(Notification to Implement Issued as of May 21, 2019)

Nelarabine (Atriance) for Acute Lymphoblastic Leukemia
(Pending Submission as of May 16, 2019)

Lorlatinib (Lorbrena) for Non-Small Cell Lung Cancer
(Pending Submission as of May 13, 2019)

Rituximab (Truxima) for Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia Biosimilar
(Pending Submission as of April 23, 2019)

Rituximab (Brand Name: TBD) for Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia Biosimilar
(Pending Submission as of April 23, 2019)

Trastuzumab (Brand Name: TBD) for Breast and Gastric Cancer Biosimilar
(Pending Submission as of April 16, 2019)

 

Find a Drug Review